FAIL (the browser should render some flash content, not this).
#
#
#
INVESTORS - SECTIONS


#
EvoraKids is the first probiotic-based, all-natural oral care chewable created to promote oral health for children 3-10 years old

#
#
Teddy's Pride is the very first probiotic for oral care for all cats and dogs that freshens breath naturally while gently and naturally whitening teeth

#
#
#
Walgreens Press Release - 2.08.2010

EvoraPlus Probiotic Oral Care Product by Oragenics, Inc. Launches In Walgreens

Oragenics, Inc.’s Acclaimed New Probiotic Oral Care Product EvoraPlus™ To Be Featured In All 7,000+ Walgreens Locations

For Immediate Release

Tampa, FL (Feb 8, 2010) – Walgreens, the country’s largest drug store chain, will offer EvoraPlus, the groundbreaking oral care probiotic mint from Florida-based biotechnology company Oragenics, Inc. (OTCBB: ORNI www.oragenics.com) chain-wide beginning March 19, 2010.  The introduction of EvoraPlus into Walgreens’ retail locations follows the successful launch of the innovative oral care product on the retailer’s website (www.walgreens.com).   EvoraPlus will now be available both at all of Walgreens more than 7,000 locations as well as its popular online destination www.walgreens.com.

Offering a revolutionary new application of probiotics, which have traditionally been used to support digestive and immune health, EvoraPlus’ probiotics are specifically designed for complete oral care.  The industry’s first 100% natural all-in-one oral care probiotic mint, EvoraPlus gently whitens teeth and alleviates bad breath while supporting gum and tooth health.

“We are extremely delighted to join with Walgreens to bring EvoraPlus to the public.  One of the country’s most outstanding retailers, Walgreens is dedicated to providing its customers with the highest quality products.  We are proud to forge our alliance with this extraordinary company and look forward to a long and successful association,” said Gerry David, Executive Vice President, Sales and Marketing for Oragenics.

Developed by Dr. Jeffrey Hillman, D.M.D., Ph.D., a chief scientific officer at Oragenics, Inc., EvoraPlus is based on more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida.  Through his research, Dr. Hillman found three strains of beneficial bacteria that help maintain an optimal balance of beneficial bacteria in the mouth, naming the patent-pending blend ProBiora3™, the active ingredient in EvoraPlus.   100% natural, EvoraPlus is made in the USA in an FDA registered and GMP certified facility ensuring both the highest quality ingredients and complete integrity.

 

About Dr. Hillman
Dr. Jeffrey Hillman founded Oragenics, Inc., to commercialize the fruits of more than 25 years of research at the Harvard-affiliated Forsyth Institute in Boston and the University of Florida.  Currently a professor emeritus at the University of Florida College of Dentistry, Dr. Hillman has continued his work at Oragenics on discovery and development of several cutting-edge health technologies. Dr. Hillman has authored or co-authored more than 125 publications and textbook chapters on subjects related to the etiology and prevention of caries (cavities), periodontal (gum) diseases and other infectious diseases and cancer. Dr. Hillman received his undergraduate training at the University of Chicago, his DMD degree from the Harvard School of Dental Medicine, and his Ph.D. from Harvard Medical School.

About Oragenics, Inc
Oragenics, Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The Company also has a number of technologies in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has offices located in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida, approximately 15 miles from the campus of the University of Florida in Gainesville, and at 3000 Bayport Drive, suite 685 in Tampa, Florida.

About Walgreens
Walgreens (www.walgreens.com) is the nation’s largest drugstore chain with fiscal 2009 sales of $63.3 billion. The company operates 7,105 drugstores in all 50 states, the District of Columbia and Puerto Rico. Walgreens provides the most convenient access to consumer goods and services and cost-effective pharmacy, health and wellness services in America through its retail drugstores, Walgreens Health Services division and Walgreens Health and Wellness division. Walgreens Health Services assists pharmacy patients and prescription drug and medical plans through Walgreens Health Initiatives Inc. (a pharmacy benefit manager), Walgreens Mail Service Inc., Walgreens Home Care Inc., Walgreens Specialty Pharmacy LLC and SeniorMed LLC (a pharmacy provider to long-term care facilities). Walgreens Health and Wellness Division includes Take Care Health Systems, the largest and most comprehensive manager of worksite health and wellness centers and in-store convenient care clinics, with more than 700 locations throughout the country.

 

 

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

MEDIA CONTACT:  For more information about EvoraPlus, visit www.evoraplus.com.   To schedule an interview with Dr. Hillman, contact Cara Downs at 818-907-5929 / cdowns@ssapr.com

 

 

CONTACT:           SSA Public Relations
(818) 907-5929
Steve Syatt
ssyatt@ssapr.com
Cara Downs
cdowns@ssapr.com

 

Click here to go back to the main Press Releases page

 
 
Teddy's Pride Website